Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SGK1 | O00141 | 4/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14018661 | 0.90 | ITGA1 (0.50) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL618067 | 0.83 | BRD4 (0.56) | MAPTLMNABRD4EDNRBEDNRA | |
| SCHEMBL3299102 | 0.81 | BRD4 (0.51) | ALDH1A1MAPTTP53BRD4 | |
| SCHEMBL30547019 | 0.73 | LMNA (0.56) | ALDH1A1MAPTLMNAHPGDHSP90AA1 | |
| SCHEMBL9843379 | 0.73 | LMNA (0.56) | ALDH1A1MAPTLMNAHPGDHSP90AA1 | |
| SCHEMBL25453798 | 0.73 | CDK1 (0.68) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL30161399 | 0.73 | CDK1 (0.68) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL14403379 | 0.72 | MEN1 (0.62) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL5383562 | 0.72 | BRD4 (0.70) | CDK1CCNB1CCNA2CDK2CDK7 | |
| SCHEMBL13615072 | 0.72 | CDK1 (0.63) | CDK1CCNB1CCNA2CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | CDK1 1159/4885CCNB1 1066/4885CCNA2 1618/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | CDK1 736/4885CCNB1 536/4885CCNA2 546/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | CDK1 736/4885CCNB1 536/4885CCNA2 546/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | CDK1 672/4885CCNB1 504/4885CCNA2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.